×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Calliditas gets controlling stake, option to buy out Genkyotex and its failed PBC drug
Fierce Biotech
Calliditas is spending a little over €20 million for a controlling stake in Genkyotex in the hope it can help revive its faltering attempts...
45 months ago
Genkyotex' NOX inhibitor candidate Fails to follow through on Phase II
Labiotech.eu
The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease. The NOX1-4 inhibitor failed to reduce...
22 months ago
Calliditas takes control of Genkyotex: expanding the rare disease pipeline
Pharmaceutical Technology
Swedish-headquartered rare disease specialist Calliditas Therapeutics has closed its acquisition of 62.7% of French biopharma company...
41 months ago
Genkyotex announces positive final results of GKT831 trial in PBC
Clinical Trials Arena
Genkyotex has reported positive final results of its Phase II trial of anti-fibrotic candidate GKT831 in primary biliary cholangitis (PBC).
58 months ago
This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis
Labiotech.eu
Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment in another Phase II study for PBC,...
22 months ago
Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients
Labiotech.eu
Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary cholangitis failed to reduce a...
22 months ago